# Forbion Growth Opportunities Fund IV

> Later-stage biopharma investment vehicle in Europe and North America. October 6 2026 announcement disclosed €2.3B raised in aggregate with Forbion Ventures VIII; individual Growth IV allocation not disclosed. About 30 investments planned across BOTH funds.

## Profile

- **Stage-based planning range:** $100K–$1M
- **Check-size evidence basis:** estimated
- **Founded:** N/A
- **Headquarters:** Netherlands
- **AUM:** N/A
- **Rounds they lead:** N/A
- **Rounds they invest:** N/A

## Links

- [Website](https://forbion.com/)

## In-depth investment analysis

## Verified mandate and fund history

This vehicle is focused on growth financing for biotech therapies with substantial unmet clinical need. The combined €2.3B is not this vehicle's individual fund size. LPs mentioned in the combined announcement must not be assigned to this fund separately without evidence.

### Source and uncertainty

Primary manager announcement: https://forbion.com/news-insights/news/forbion-raises-23-billion-across-two-new-funds/. Amounts for other vehicles, firm AUM, LP commitments and targets are **not** interchangeable. Fund-level fees, returns and undisclosed allocations are not estimated.

## Research sources

- [Primary manager statement](https://forbion.com/news-insights/news/forbion-raises-23-billion-across-two-new-funds/)

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/fund/forbion-growth-opportunities-fund-iv